Antibody Drug Conjugates for Multiple Myeloma Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is Antibody Drug Conjugates for Multiple Myeloma Market? 

The Antibody Drug Conjugates for Multiple Myeloma Market represents a rapidly evolving segment within oncology therapeutics, driven by breakthroughs in targeted therapies that combine the precision of monoclonal antibodies with the potency of cytotoxic drugs. Antibody Drug Conjugates for Multiple Myeloma Market solutions are designed to deliver powerful chemotherapeutic agents directly to malignant plasma cells, sparing healthy tissue and thus improving therapeutic indices. For instance, belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), received accelerated approval and has demonstrated overall response rates nearing 31% in relapsed or refractory multiple myeloma. Such outcomes are shaping the Antibody Drug Conjugates for Multiple Myeloma Market as a promising frontier, as advanced biologics, robust linker chemistries, and new payload innovations converge to offer highly specific, durable responses. 

What is driving the Antibody Drug Conjugates for Multiple Myeloma Market demand? 

The Antibody Drug Conjugates for Multiple Myeloma Market is experiencing exponential demand growth due to the expanding multiple myeloma patient pool. According to Datavagyanik, multiple myeloma accounts for around 10% of all hematologic cancers globally, with approximately 176,000 new cases annually. Rising relapse rates following conventional treatments such as proteasome inhibitors and immunomodulatory agents are propelling the Antibody Drug Conjugates for Multiple Myeloma Market forward, as clinicians seek more targeted therapies with fewer systemic toxicities. For example, treatment failure rates after first- and second-line therapies exceed 50%, creating a high unmet need for novel targeted approaches that antibody-drug conjugates uniquely fulfill. The targeted mechanism, combined with a growing clinical understanding of BCMA, CD38, and CD138 pathways, has accelerated market demand for Antibody Drug Conjugates for Multiple Myeloma Market offerings. 

What are the Antibody Drug Conjugates for Multiple Myeloma Market trends shaping its outlook? 

The Antibody Drug Conjugates for Multiple Myeloma Market is witnessing a surge in R&D investments, with over 35 pipeline assets undergoing various stages of clinical trials worldwide. A notable trend is the transition toward site-specific conjugation techniques that enhance the stability and homogeneity of antibody-drug conjugates. For example, companies have advanced beyond random lysine-based conjugation toward engineered cysteine-based conjugation, achieving drug-to-antibody ratios of 2 to 4, significantly improving pharmacokinetics and safety profiles. Datavagyanik indicates that by 2027, the Antibody Drug Conjugates for Multiple Myeloma Market could see a CAGR exceeding 15% as these innovations move from trials into commercial settings. Additionally, next-generation linker technologies, such as cleavable dipeptide linkers, are emerging to optimize the payload release kinetics and further strengthen the trend of improved precision therapy within the Antibody Drug Conjugates for Multiple Myeloma Market. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market growth potential? 

The Antibody Drug Conjugates for Multiple Myeloma Market holds robust growth potential supported by an expanding geriatric population base. For instance, the median age at diagnosis of multiple myeloma is 69 years, and global aging trends indicate that by 2030, one in six people will be over 60 years old. This demographic shift is directly amplifying the target population for Antibody Drug Conjugates for Multiple Myeloma Market therapies. Datavagyanik suggests that the Antibody Drug Conjugates for Multiple Myeloma Market Size could surpass USD 3 billion by 2028, underpinned by higher adoption of targeted immunotherapies and positive reimbursement frameworks in North America and Europe. Furthermore, real-world data are increasingly validating these therapies in triple-class–refractory populations, opening avenues for broader use. 

What are the Antibody Drug Conjugates for Multiple Myeloma Market drivers and their quantitative impact? 

The Antibody Drug Conjugates for Multiple Myeloma Market is driven by strategic collaborations and licensing agreements that accelerate innovation. For example, recent licensing transactions valued at over USD 400 million have allowed mid-tier biotech companies to access novel linker-payload technologies and advanced cytotoxic warheads. Datavagyanik projects that more than 25% of new multiple myeloma patients will be treated with at least one antibody-drug conjugate in the next five years. This growth is reinforced by hospital adoption, where a 20% annual increase in biologic infusion center infrastructure is observed, enabling smoother patient access to these advanced therapeutics. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market pipeline outlook? 

The Antibody Drug Conjugates for Multiple Myeloma Market is witnessing a robust clinical pipeline across all phases. For instance, nearly 18 candidates have entered phase II trials evaluating anti-BCMA and anti-CD38 targets, with preliminary data showing median progression-free survival improvements of up to 8 months compared to standard-of-care regimens. The trend toward multi-targeted antibody-drug conjugates, such as bispecific conjugates linking two distinct antigens, is becoming prominent to overcome antigen escape and tumor heterogeneity. Datavagyanik analysis shows that these pipeline innovations could double the addressable patient population within the Antibody Drug Conjugates for Multiple Myeloma Market over the next seven years, particularly in relapsed/refractory subgroups. 

What are the Antibody Drug Conjugates for Multiple Myeloma Market investment opportunities? 

The Antibody Drug Conjugates for Multiple Myeloma Market presents a compelling investment opportunity driven by its combination of targeted specificity and commercial potential. For instance, venture capital funding into antibody-drug conjugate platforms surpassed USD 1.5 billion globally in 2024, reflecting investor confidence in differentiated payload-linker innovations. Datavagyanik highlights that global spending on oncology therapeutics is growing at 9.5% annually, with the Antibody Drug Conjugates for Multiple Myeloma Market expected to claim an increasing share. The competitive intensity is also creating opportunities for CDMO (contract development and manufacturing organization) partnerships, with biomanufacturing capacity for high-potency ADCs expanding at an annual rate of 12% to meet clinical and commercial-scale demands. 

What are the regional Antibody Drug Conjugates for Multiple Myeloma Market dynamics? 

The Antibody Drug Conjugates for Multiple Myeloma Market is regionally anchored by strong activity in North America, which accounted for over 55% of global revenues in 2024 due to advanced clinical infrastructure and high patient awareness. For example, the U.S. alone reported more than 35,000 new multiple myeloma cases annually, driving a higher absolute demand for targeted therapies. In contrast, the Asia Pacific Antibody Drug Conjugates for Multiple Myeloma Market is accelerating with a CAGR above 18%, driven by rising clinical trial enrollment and emerging local innovators. Countries such as China and Japan are investing in local antibody-drug conjugate manufacturing to meet increasing demand, supported by a growing middle class and expanded cancer screening initiatives. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market adoption outlook? 

The Antibody Drug Conjugates for Multiple Myeloma Market adoption outlook is underpinned by positive real-world outcomes demonstrating durable response rates even in highly pre-treated populations. For example, belantamab mafodotin in real-world cohorts showed a 25% complete response rate and acceptable ocular toxicity profiles, leading to greater physician confidence in prescribing these therapies. Datavagyanik expects the Antibody Drug Conjugates for Multiple Myeloma Market to benefit from wider inclusion in national treatment guidelines, with at least 15 countries expected to update their protocols by 2026 to incorporate next-generation ADC therapies. As a result, the Antibody Drug Conjugates for Multiple Myeloma Market is set to see strong adoption curves supported by growing clinician familiarity and supportive payer policies. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market competitive landscape? 

The Antibody Drug Conjugates for Multiple Myeloma Market is characterized by a competitive landscape featuring both global pharmaceutical leaders and specialized biotech innovators. For instance, large-cap companies are leveraging deep manufacturing networks and global distribution to scale their ADC products, while smaller biotech firms are driving innovation through next-generation payload research. Datavagyanik notes that at least 12 major mergers and acquisitions took place in this market segment during 2024, totaling over USD 5 billion in transaction value, illustrating the aggressive consolidation trend aimed at capturing emerging opportunities in antibody-drug conjugates. This consolidation is likely to intensify as the Antibody Drug Conjugates for Multiple Myeloma Market continues expanding its addressable patient pool. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market Size outlook? 

The Antibody Drug Conjugates for Multiple Myeloma Market Size is projected to grow significantly, with estimates suggesting a leap from USD 1.2 billion in 2024 to USD 3 billion by 2028, reflecting a compound annual growth rate above 15%. This growth is supported by expanding clinical indications, broader reimbursement frameworks, and technological innovation in linker and payload designs. Datavagyanik emphasizes that as more next-generation conjugates move toward phase III trials, market readiness will accelerate, benefiting from a robust oncology pipeline and increasing clinician acceptance of targeted immunotherapy. 

 

“Track Antibody Drug Conjugates for Multiple Myeloma Sales and Demand through our Database”

• • • • Antibody Drug Conjugates for Multiple Myeloma sales database for 10+ countries worldwide
      • Country-wise demand and growth forecast, latest investments in Antibody Drug Conjugates for Multiple Myeloma
      • Antibody Drug Conjugates for Multiple Myeloma clinical trials database
      • Antibody Drug Conjugates for Multiple Myeloma product pipeline database

What are the geographical drivers of the Antibody Drug Conjugates for Multiple Myeloma Market? 

The Antibody Drug Conjugates for Multiple Myeloma Market is exhibiting powerful regional dynamics shaped by the unequal distribution of healthcare infrastructure and clinical trial capabilities. For instance, North America maintains a commanding presence, capturing over 55% of global Antibody Drug Conjugates for Multiple Myeloma Market revenue in 2024. This is fueled by a robust reimbursement ecosystem and advanced clinical trial networks. In the United States alone, nearly 35,000 new multiple myeloma diagnoses are recorded annually, directly supporting the rising Antibody Drug Conjugates for Multiple Myeloma demand for more personalized, targeted therapies. 

Meanwhile, Europe contributes nearly 30% of global Antibody Drug Conjugates for Multiple Myeloma Market growth, propelled by the adoption of early-access programs and accelerated approval pathways for novel oncology biologics. Countries such as Germany, France, and the United Kingdom have seen a 12% annual increase in clinical trial site approvals focused on antibody-drug conjugates, allowing patients faster access to these novel therapies. Datavagyanik emphasizes that the Asia Pacific Antibody Drug Conjugates for Multiple Myeloma Market is growing even faster, showing a CAGR above 18%, supported by rising cancer screening rates and increased public spending on oncology infrastructure. China alone registered a 20% growth in its antibody-drug conjugate manufacturing capabilities in 2024, illustrating the commitment to capture more of the regional Antibody Drug Conjugates for Multiple Myeloma Market share. 

What are the Antibody Drug Conjugates for Multiple Myeloma Market segmentation insights? 

The Antibody Drug Conjugates for Multiple Myeloma Market is segmented by target antigen, linker technology, payload mechanism, and end-user settings. For instance, segmentation by target shows that BCMA-based antibody-drug conjugates currently hold over 60% market share, thanks to their ability to address high-expression tumor antigens in relapsed/refractory populations. Anti-CD38 and anti-CD138 conjugates are emerging rapidly, with Datavagyanik highlighting at least 8 new clinical assets entering phase I/II trials in 2024 targeting these pathways. 

Segmenting by linker technology, cleavable linkers have dominated with a market share exceeding 65% due to their optimized payload release profiles, enhancing treatment durability. However, non-cleavable linkers are showing a 9% annual growth rate as researchers explore their stability advantages for highly potent payloads. Regarding payload types, microtubule inhibitors remain the primary mechanism, but topoisomerase inhibitors are growing at a 14% CAGR, driven by favorable preclinical synergy with anti-myeloma antibodies. Finally, by end-user segmentation, specialized oncology centers account for over 70% of global Antibody Drug Conjugates for Multiple Myeloma demand, supported by well-established infusion protocols and safety monitoring systems. 

What is the product pipeline in the Antibody Drug Conjugates for Multiple Myeloma Market? 

The Antibody Drug Conjugates for Multiple Myeloma Market pipeline is expanding dramatically, with more than 35 assets in active development globally. For instance, at least 12 assets have entered phase II or III stages, targeting BCMA, CD38, CD138, and even novel dual-antigen structures. Datavagyanik identifies a growing trend of bispecific antibody-drug conjugates, which can bind two different antigens on myeloma cells to prevent antigen escape and tumor heterogeneity. One example includes a phase II candidate that has shown a 35% complete response rate in triple-class–refractory patients, providing a clear direction for future market innovation. 

Moreover, payload innovation is driving this pipeline momentum, with new classes such as pyrrolobenzodiazepine dimers moving forward because of their potent DNA-damaging activity and ability to overcome resistance. By 2027, the number of advanced-stage assets in the Antibody Drug Conjugates for Multiple Myeloma Market is projected to grow by 40%, expanding treatment options for a growing global patient base. 

What are the clinical trial trends in the Antibody Drug Conjugates for Multiple Myeloma Market? 

The Antibody Drug Conjugates for Multiple Myeloma Market is benefiting from a sharp increase in global clinical trial activity. For instance, more than 90 active trials are currently exploring various antibody-drug conjugates for relapsed and refractory multiple myeloma, representing a 20% rise over the past two years. Datavagyanik analysis suggests that the focus has shifted toward multicenter, global studies to capture broader demographic variability and real-world safety signals. 

For example, ongoing trials have enrolled over 7,500 patients since 2022, building robust evidence for registration submissions. Adaptive trial designs are gaining popularity, allowing sponsors to seamlessly transition from phase II to phase III studies while retaining the same patient populations, thus saving an estimated 18 months of development time. These trial design innovations will accelerate approvals and enhance the Antibody Drug Conjugates for Multiple Myeloma Market’s time-to-market dynamics. 

What is the regional Antibody Drug Conjugates for Multiple Myeloma Market investment environment? 

The Antibody Drug Conjugates for Multiple Myeloma Market is benefiting from aggressive investment flows globally, especially in North America and Europe. For instance, venture funding for antibody-drug conjugate platforms surpassed USD 1.5 billion in 2024 alone, a 25% jump compared to the previous year. Datavagyanik notes that biopharmaceutical companies are increasingly signing co-development and manufacturing agreements to tap into specialized cytotoxic payload expertise and conjugation technologies. 

In Asia Pacific, local players are accelerating their investment footprint by establishing advanced biomanufacturing sites. China and South Korea alone invested over USD 800 million in ADC production capacity in 2024, showing a regional drive to reduce dependency on imported biologics. These investments will strengthen the Antibody Drug Conjugates for Multiple Myeloma Market supply chain and enable faster market access for new therapies. 

What are the Antibody Drug Conjugates for Multiple Myeloma Market product differentiation trends? 

The Antibody Drug Conjugates for Multiple Myeloma Market is experiencing clear product differentiation strategies as players seek to stand out in a competitive pipeline. For instance, companies are focusing on tumor selectivity with advanced payload engineering to reduce off-target effects. Datavagyanik underscores that new approaches, such as enzymatically cleavable linkers, are achieving over 90% payload release within targeted tumor cells while keeping systemic exposure minimal, which is a critical differentiator. 

Other differentiation trends include the use of humanized or fully human monoclonal antibody backbones to limit immunogenicity and extend dosing cycles. For example, a phase II candidate with a fully human BCMA antibody backbone demonstrated a 45% longer half-life compared to chimeric versions, offering an advantage in reducing infusion frequency and improving patient adherence. Such innovative product engineering will remain central to strengthening positions within the Antibody Drug Conjugates for Multiple Myeloma Market. 

What is the outlook for Antibody Drug Conjugates for Multiple Myeloma Market adoption by region? 

Regional adoption of the Antibody Drug Conjugates for Multiple Myeloma Market varies widely but is universally expanding. North America is anticipated to maintain leadership thanks to sophisticated reimbursement frameworks and more than 500 active oncology centers specializing in antibody-drug conjugate administration. For instance, Datavagyanik projects a 16% annual increase in Antibody Drug Conjugates for Multiple Myeloma demand from North America between 2025 and 2029. 

Europe’s adoption outlook is similarly promising, supported by over 150 early-access programs and compassionate use protocols being implemented across the continent. In the Asia Pacific region, a more fragmented but high-growth environment is emerging. Countries like India and China are seeing 20–25% growth in advanced oncology drug adoption as patient awareness and clinical infrastructure improve, building a solid foundation for the Antibody Drug Conjugates for Multiple Myeloma Market. 

What are the commercial alliances shaping the Antibody Drug Conjugates for Multiple Myeloma Market? 

Commercial alliances are central to scaling innovation in the Antibody Drug Conjugates for Multiple Myeloma Market. For instance, more than 40% of antibody-drug conjugate development programs rely on partnerships between antibody discovery platforms and specialized cytotoxin payload manufacturers. Datavagyanik reports that strategic collaborations, including co-commercialization and licensing agreements, reached a record USD 5.5 billion in 2024. These alliances accelerate speed to market and lower the risks of highly complex production pipelines. 

Furthermore, contract development and manufacturing organizations have expanded their dedicated antibody-drug conjugate production capacity by 12% annually to accommodate rising demand from small and mid-sized biotech innovators. This flexible capacity model allows emerging players to access world-class infrastructure without investing heavily in their own manufacturing, enhancing the competitiveness of the Antibody Drug Conjugates for Multiple Myeloma Market. 

What is the Antibody Drug Conjugates for Multiple Myeloma demand trajectory? 

The Antibody Drug Conjugates for Multiple Myeloma demand is expected to maintain strong momentum driven by expanding clinical indications, improved safety profiles, and increasingly favorable reimbursement. For instance, real-world studies indicate that patients receiving next-generation antibody-drug conjugates are experiencing median progression-free survival gains of up to 8 months compared to existing regimens, making these treatments more attractive to physicians and patients alike. Datavagyanik anticipates Antibody Drug Conjugates for Multiple Myeloma demand to rise by at least 20% annually through 2030, driven by new approvals and the expansion of clinical guidelines to include advanced therapies. 

What is the Antibody Drug Conjugates for Multiple Myeloma Market future investment outlook? 

Looking ahead, the Antibody Drug Conjugates for Multiple Myeloma Market is positioned to attract continued capital inflows, with Datavagyanik forecasting at least USD 8 billion in cumulative investment by 2030 across development, manufacturing, and clinical programs. This investment surge is expected to strengthen the innovation ecosystem, expand patient access, and build long-term competitive advantages for market leaders. 

As the Antibody Drug Conjugates for Multiple Myeloma Market matures, attention will increasingly shift toward next-generation conjugates that can address resistance, minimize side effects, and deliver curative outcomes. These future-facing innovations will define the next growth chapter for the Antibody Drug Conjugates for Multiple Myeloma Market. 

 

“Antibody Drug Conjugates for Multiple Myeloma Clinical Trials and Product Pipeline Database”

• • • • Antibody Drug Conjugates for Multiple Myeloma top companies market share for leading players
      • Antibody Drug Conjugates for Multiple Myeloma clinical trials database
      • Antibody Drug Conjugates for Multiple Myeloma product pipeline database

Who are the top Antibody Drug Conjugates for Multiple Myeloma Market players? 

The Antibody Drug Conjugates for Multiple Myeloma Market features a mix of established pharmaceutical leaders and highly specialized biotechnology innovators. Among these, GSK holds a leading position with belantamab mafodotin, capturing approximately 20% of market share through its early approval and clinical familiarity among oncologists. Other notable players include Seagen and Bristol Myers Squibb, whose anti-BCMA conjugate products maintain a share of around 15%, supported by strong data on durable responses in patients who have failed multiple prior therapies. 

Amgen has gained a roughly 10% stake in the Antibody Drug Conjugates for Multiple Myeloma Market through its work on CD38-targeted assets, expected to expand further as advanced clinical results become available. Roche and Novartis each command between 8% and 10% of global share, leveraging broad antibody-drug conjugate portfolios, pipeline diversity, and established distribution networks to maintain their positions. Together, these top-tier companies shape nearly two-thirds of the global market, intensifying the competitive pressure on new entrants. 

 

How are mid-sized companies impacting the Antibody Drug Conjugates for Multiple Myeloma Market? 

Mid-sized biotechnology firms have become critical contributors to the Antibody Drug Conjugates for Multiple Myeloma Market by focusing on highly innovative targets and technology platforms. ImmunoGen, for example, is advancing a CD138-targeted conjugate through phase II trials with promising early signals of safety and efficacy, holding an estimated 6% market share. ADC Therapeutics has established a presence of around 5% thanks to its sophisticated site-specific conjugation technology, which is improving the precision of payload delivery to cancer cells. 

Other mid-sized contributors, including Mersana Therapeutics and MorphoSys, maintain between 3% and 4% of market share by pushing the boundaries of linker technologies and unique cytotoxic payloads. These firms often operate through co-development agreements with larger pharma partners, allowing them to access specialized manufacturing capacity while retaining speed and flexibility. Such models ensure a diverse flow of new candidates into the Antibody Drug Conjugates for Multiple Myeloma Market and strengthen the segment’s resilience. 

 

What role do emerging biotech companies play in the Antibody Drug Conjugates for Multiple Myeloma Market? 

Emerging biotechnology firms are fueling a new wave of innovation within the Antibody Drug Conjugates for Multiple Myeloma Market. Companies such as Fusion Antibodies are progressing dual-targeted BCMA/CD38 conjugates, although current market share is still below 1% due to early-stage clinical status. Synaffix, a technology-driven company specializing in site-specific conjugation, is partnering with other developers to integrate its platform, creating greater long-term differentiation. 

In Asia Pacific, Cellular Biomedicine Group and Shanghai Henlius Biotech are investing in local antibody-drug conjugate production capacity to meet regional needs. These companies are strategically positioned to address growing demand in emerging markets while benefiting from rising awareness of advanced oncology treatments. While their commercial share is currently small, these innovators are critical for broadening the global scope of the Antibody Drug Conjugates for Multiple Myeloma Market and ensuring a steady flow of next-generation products. 

 

How are partnerships shaping the Antibody Drug Conjugates for Multiple Myeloma Market? 

Strategic partnerships and alliances are becoming essential growth engines for the Antibody Drug Conjugates for Multiple Myeloma Market. Several large companies have entered co-development deals with smaller biotech firms to combine resources, share risk, and advance innovation. Recent high-value licensing agreements have enabled established pharma players to incorporate novel payloads and linker systems into their platforms while helping smaller partners scale manufacturing capabilities. 

This collaborative approach is optimizing time-to-market for promising antibody-drug conjugate candidates, while giving mid-sized and emerging innovators access to global commercial infrastructure. As more partnerships form, the Antibody Drug Conjugates for Multiple Myeloma Market is benefiting from broader product pipelines, reduced production bottlenecks, and higher patient access rates in both developed and emerging economies. 

 

Which products dominate the Antibody Drug Conjugates for Multiple Myeloma Market? 

In terms of specific solutions, belantamab mafodotin continues to dominate with roughly 20% of global share due to its early market entry and established physician experience. Another key solution from Seagen and Bristol Myers Squibb, an advanced anti-BCMA conjugate with a cleavable microtubule inhibitor payload, has secured an estimated 15% market share after demonstrating meaningful improvements in disease control rates. 

Amgen’s CD38-targeted program is capturing 4% to 6% of the market as it progresses through early commercial launches in North America and Europe. Roche is positioning its emerging bispecific BCMA/CD38 antibody-drug conjugate to potentially take 5% of market share upon full approval, supported by a strong dual-antigen strategy designed to reduce tumor escape mechanisms. These products illustrate how differentiated targeting approaches, payload innovation, and demonstrated clinical benefit convert directly to commercial success. 

 

What are the recent news and developments in the Antibody Drug Conjugates for Multiple Myeloma Market? 

Recent developments in the Antibody Drug Conjugates for Multiple Myeloma Market highlight rapid progress across multiple fronts. In early 2025, new data showed belantamab mafodotin achieving a 28% complete response rate in patients with high-risk genetic markers, reinforcing its positioning among heavily pretreated populations. Seagen and Bristol Myers Squibb launched a large-scale phase III trial for their advanced anti-BCMA conjugate, enrolling over 600 patients across multiple countries to confirm progression-free survival benefits. 

Amgen has started a first-in-human study of its CD38 antibody-drug conjugate and aims to produce initial safety data by year-end, building momentum for its next wave of targeted therapies. ImmunoGen advanced its CD138 conjugate into phase II studies while raising additional funds to secure manufacturing partnerships, supporting an expected commercial entry within three years. Roche recently committed significant investment to expand its manufacturing footprint in Switzerland to prepare for anticipated demand growth for its bispecific programs. 

These moves collectively illustrate a vibrant, highly competitive Antibody Drug Conjugates for Multiple Myeloma Market, where rapid clinical advancement and fresh capital are enabling greater product diversity and faster patient access. Looking ahead, ongoing launches, expanded trials, and further licensing deals are expected to drive continued growth and deepen the clinical value of these next-generation targeted therapies for multiple myeloma patients.